Investigating Agile Adaptation for Project Development

Agile methodologies adaptation in software companies is an accepted norm.Rapid application development and efficient deliverables being the premise. The changing business needs, cost effectiveness and timely delivery are catered to by agile methods. Different software development models are in the literature and also are being used by the industry. Few companies have adopted agile, few are gearing up for and few are in transition. We investigated agile presence in a software company.Project management is an evolving art with innovative methods being added up.The aim of this paper is to tease about project management challenges, agile, agile transition in companies and a comparison of conventional software engineering practices with agile process model.This paper takes stock of the current status of quality in software projects and to add on quality process improvement strategies. The results presented here are after a qualitative interview study with one cross function team using streamline development framework in agile development

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Speedcontrolofseparatelyexciteddcmotorusingpowerelectronicconverter

In a modern technology the use of power electronic devices in the control strategies of electrical drives is increasing. The speed of a DC motor can be varied by controlling the field flux, the armature resistance or the terminal voltage applied to the armature circuit. The three most common speed control methods are field resistance control, armature voltage control, and armature resistance control. But here a technique of drive has been used for DC motor's speed control is chopper and some power electronics devices. It has been shown here the use of chopper and power electronics devices which paves the way of controlling also torque and speed characteristics of DC motor. Now the simulation of model is done and analysed in MATLAB (Simulink) under varying speed and torque conditio

Bleeding control measures during oral and maxillofacial surgical procedures: A systematic review

Surgical bleeding can be associated with an increased risk of morbidity and mortality across all surgical areas. Thus, to avoid complications related to excessive bleeding, numerous products have been developed to achieve hemostasis. The thorough knowledge of these hemostatic measures is required for good results. The aim of the study is to compare the different methods to control bleeding in oral and maxillofacial surgery. An extensive systematic literature search was performed in PubMed, Google search using combination of keywords such as bleeding, bleeding control methods, oral surgery, Gelfoam, vasoconstrictors, Chitosan, Floseal, haemcoagulase, Gelatin Sponge, Suturing, and Cautery. The inclusion criteria for the study were articles in English, articles published between January 1, 1990 to June 30, 2016, studies that provide information about bleeding control procedures, complications during head, neck, and face surgery procedures and hemostatic agent and articles based on observational studies and original articles. Exclusion criteria for the study were studies that provided inadequate information, systemic review, research papers, case reports, letters to editor and studies based on animals other than human beings. Total 11 articles were selected for the analysis which included head, face, and neck procedures with/without using bleeding control measures such as pressure application, suturing, cautery, ligation of blood vessel, application of Ankaferd blood stopper, chitosan, Floseal®, thrombin–gelatin matrix (Tissel®)/fibrin glue, Gelfoam, and tranexamic acid. Conventional methods are insufficient to control extensive bleeding. However, newer methods or combinations of these methods are required to achieve adequate hemostasis. All hemostatic measures were not covered in this review